A Phase II Study of ZD 1839 (IRESSA) in Patients With Advanced Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Gefitinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 03 Jun 2010 Planned number of patients changed from 27 to 38 as reported by ClinicalTrials.gov record.
- 03 Jun 2010 Planned end date (1 Mar 2011) added as reported by ClinicalTrials.gov record.